Trials / Terminated
TerminatedNCT05999799
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1070806 | GSK1070806 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-11-16
- Primary completion
- 2025-07-23
- Completion
- 2025-07-23
- First posted
- 2023-08-21
- Last updated
- 2025-11-17
Locations
89 sites across 17 countries: United States, Argentina, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Italy, Japan, Mexico, Panama, Poland, South Korea, Spain, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05999799. Inclusion in this directory is not an endorsement.